Compare NERV & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NERV | DERM |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.1M | 190.3M |
| IPO Year | 2014 | 2021 |
| Metric | NERV | DERM |
|---|---|---|
| Price | $4.43 | $7.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $10.50 | ★ $12.67 |
| AVG Volume (30 Days) | 132.9K | ★ 200.6K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | N/A | ★ N/A |
| Revenue | $41,175,600.00 | ★ $61,858,000.00 |
| Revenue This Year | N/A | $39.72 |
| Revenue Next Year | N/A | $63.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $1.93 | $4.31 |
| 52 Week High | $12.46 | $9.56 |
| Indicator | NERV | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 66.52 |
| Support Level | $3.87 | $7.25 |
| Resistance Level | $4.73 | $8.29 |
| Average True Range (ATR) | 0.33 | 0.39 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 19.49 | 85.50 |
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.